Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model

International Immunopharmacology

Volumn 10, Issue 2, 2010, Pages 252-258

  Wang, Ya juan ^a   Jiang, Ya li ^a   Tang, Hui fang ^a   Zhao, Chun zhen ^a   Chen, Ji qiang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic obstructive pulmonary disease; Inflammation; Phosphodiesterase 4 inhibitor; Rats; Zl n 91

Indexed keywords

CYCLIC AMP; GELATINASE B; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; TOXIC GAS; UNCLASSIFIED DRUG; ZL N 91;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; INFLAMMATION; INFLAMMATORY CELL; LUNG DISEASE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; SMOOTH MUSCLE RELAXATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; FURANS; LIPOPOLYSACCHARIDES; LUNG; MALE; MATRIX METALLOPROTEINASE 9; NEUTROPHILS; PEROXIDASE; PHENYL ETHERS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; SMOKING;

EID: 74749104409     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.11.008     Document Type: Article

References (31)

1. Currie G.P., Butler C.A., Anderson W.J., and Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment. Br J Clin Pharmacol 65 6 (2008) 803-810
2. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
3. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8 (2008) 183-192
4. Barnes P.J. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 8 3 (2008) 300-307
5. Barnes P.J. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 5 (2008) 857-864
6. Martorana P.A., Beume R., Lucattelli M., Wollin L., and Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoking. Am J Respir Crit Care Med 172 (2005) 848-853
7. Lunniss C.J., Cooper A.W., Eldred C.D., Kranz M., Lindvall M., Lucas F.S., et al. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett 19 (2009) 1380-1385
8. Neville K.A., Szefler S.J., Abdel-Rahman S.M., Lahu G., Zech K., Herzog R., et al. Single-dose pharmacokinetics of roflumilast in children and adolescents. J Clin Pharmacol 48 8 (2008) 978-985
9. Rennard S., Knobil K., Rabe K.F., Morris A., Schachter N., Locantore N., et al. The efficacy and safety of cilomilast in COPD. Drugs 68 Suppl 2 (2008) 3-57
10. De Visser Y.P., Walther F.J., Laghmani E.H., van Wijngaarden S., Nieuwland K., and Wagenaar G.T. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 31 3 (2008) 633-644
11. Vestbo J., Tan L., Atkinson G., and Ward J. A controlled trial of 6 weeks' treatment with a novel inhaled PDE4 inhibitor in COPD. Eur Respir J 33 5 (2009) 1039-1044
12. Ma R.H., Yang B.Y., and Wu C.Y. A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells. Int Immunopharmacol 8 (2008) 1408-1417
13. Mizutani N., Fuchikami J., Takahashi M., Nabe T., Yoshino S., and Kohno S. Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull 32 (2009) 1559-1564
14. Groneberg D.A., and Chung K.F. Models of chronic obstructive pulmonary disease. Respir Res 5 (2004) 18
15. Ge Z.H., and Tan T. Miao Nationality's relieve cough and reduce phlegm herb interfere the levels of IL-8 and TNF-α in bronchoalveolar larvage fluid in the obstructive emphysema rat models. Chin J Pract Chin Mod Med 4 17 (2004) 2913-2916
16. Takeuchi Y., Takahashi M., and Fuchikami J. Vulnerability of gastric mucosa to prednisolone in rats chronically exposed to cigarette smoke. J Pharm Sci 106 (2008) 585-592
17. Luo B.L., Niu R.C., Feng J.T., Hu C.P., Xie X.Y., and Ma L.J. Down-regulation of secretory leukocyte proteinase inhibitor in chronic obstructive lung disease: the role of TGF-beta/Smads signaling pathways. Arch Med Res 39 (2008) 388-396
18. Tang H.F., Chen J.Q., Xie Q.M., Zheng X.Y., Zhu Y.L., Adicock I., et al. The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats. Biochim Biophys Acta 1762 (2006) 525-532
19. Tang H.F., Song Y.H., Chen J.C., Chen J.Q., and Wang P. Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Respir Crit Care Med 171 8 (2005) 823-828
20. Higashimoto Y., Iwata T., Okada M., Satoh H., Fukuda K., and Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 103 (2009) 1231-1238
21. Churg A., Wang R., Wang X., Onnervik P.O., Thim K., and Wright J.L. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62 (2007) 706-713
22. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108 (2001) 71-80
23. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 (1998) ż351-ż370
24. Chorostowska-Wynimko J., Kus J., and Skopińska-Różewska E. Teophylline inhibits free oxygen radicals production by human monocytes via phosphodiesterases inhibition. J Physiol Pharmacol 58 suppl5 (2007) 95-103
25. Hansen G., Jin S., Umetsu D.T., and Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97 12 (2000) 6751-6756
26. Mehats C., Jin S.L., Wahlstrom J., Law E., Umetsu D.T., and Conti M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17 13 (2003) 1831-1841
27. Deng Y.M., Xie Q.M., Tang H.F., Sun J.G., Deng J.F., Chen J.Q., and Yang S.Y. Effects of ciclamilast, a new PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur J Pharmacol 547 (2006) 125-135
28. Barnes A.P., Livera G., Huanq P., Sun C., O'Neal W.K., Conti M., et al. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280 9 (2005) 7997-8003
29. Liu S., Veilleux A., Zhang L., Young A., Kwok E., Laliberté F., et al. Dynamic activation of cystic fibrosis transmenbrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther 341 2 (2005) 846-854
30. Kodimuthali A., Labaris S.S., and Pal M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem 51 18 (2008) 5471-5489
31. Barnes P.J. Emerging pharmacotherapies for COPD. Chest 134 6 (2008) 1278-1286